- Home
- EVER vs OCS Comparison
EVER vs OCS Comparison
Compare EVER & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVER
- OCS
- Stock Information
- Founded
- EVER 2008
- OCS 2003
- Country
- EVER United States
- OCS Switzerland
- Employees
- EVER N/A
- OCS N/A
- Industry
- EVER Computer Software: Programming Data Processing
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- EVER Technology
- OCS Health Care
- Exchange
- EVER Nasdaq
- OCS Nasdaq
- Market Cap
- EVER 960.3M
- OCS 1.0B
- IPO Year
- EVER 2018
- OCS N/A
- Fundamental
- Price
- EVER $24.16
- OCS $19.28
- Analyst Decision
- EVER Strong Buy
- OCS Strong Buy
- Analyst Count
- EVER 6
- OCS 3
- Target Price
- EVER $32.50
- OCS $35.33
- AVG Volume (30 Days)
- EVER 398.2K
- OCS 30.1K
- Earning Date
- EVER 08-04-2025
- OCS 05-08-2025
- Dividend Yield
- EVER N/A
- OCS N/A
- EPS Growth
- EVER N/A
- OCS N/A
- EPS
- EVER 1.03
- OCS N/A
- Revenue
- EVER $575,757,000.00
- OCS $847,333.00
- Revenue This Year
- EVER $32.07
- OCS $18.70
- Revenue Next Year
- EVER $11.08
- OCS $1,059.78
- P/E Ratio
- EVER $23.46
- OCS N/A
- Revenue Growth
- EVER 113.43
- OCS N/A
- 52 Week Low
- EVER $16.63
- OCS $10.79
- 52 Week High
- EVER $30.03
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- EVER 47.85
- OCS 51.81
- Support Level
- EVER $24.11
- OCS $18.64
- Resistance Level
- EVER $26.74
- OCS $19.73
- Average True Range (ATR)
- EVER 0.83
- OCS 0.58
- MACD
- EVER -0.07
- OCS -0.07
- Stochastic Oscillator
- EVER 33.20
- OCS 36.57
About EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.